BFC Planning’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$407K Sell
10,741
-319
-3% -$14.7K 0.02% 672
2026
Q2
$530K Sell
11,060
-3,621
-25% -$156K 0.02% 584
2026
Q1
$540K Sell
14,681
-16,812
-53% -$797K 0.02% 542
2025
Q4
$1.6M Buy
31,493
+25,358
+413% +$1.3M 0.07% 267
2025
Q3
$340K Sell
6,135
-379
-6% -$22.2K 0.02% 485
2025
Q2
$450K Buy
6,514
+671
+11% +$45.6K 0.04% 388
2025
Q1
$406K Sell
5,843
-194
-3% -$16K 0.04% 383
2024
Q4
$519K Sell
6,037
-2,550
-30% -$276K 0.04% 326
2024
Q3
$1.02M Buy
+8,587
New +$1.15M 0.09% 198

Other funds holding NVO

BFC Planning's NVO Position: Q3 2026 in Review

BFC Planning reduced its Novo Nordisk (NVO) stake by 2.9% in Q3 2026, selling an estimated $14.7K and leaving 10,741 shares worth $407K. The position accounts for 0.02% of the portfolio, ranked #672.

BFC Planning first reported a position in NVO in Q3 2024 and has held it in 9 quarters since. The position peaked at $1.6M in Q4 2025. 1,061 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • BFC Planning held 10,741 shares of Novo Nordisk worth $407K as of Q3 2026.
  • BFC Planning sold 319 Novo Nordisk shares in Q3 2026, an estimated $14.7K.
  • Novo Nordisk made up 0.02% of BFC Planning's portfolio in Q3 2026, its #672 holding.
  • BFC Planning first reported a position in Novo Nordisk in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Novo Nordisk position peaked at $1.6M in Q4 2025.
  • 1,061 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.